Antibodies as therapeutic agents: vive la renaissance!

被引:33
作者
Stockwin, LH [1 ]
Holmes, S [1 ]
机构
[1] Domantis Ltd, Cambridge CB1 6GS, England
关键词
antibody; cancer; Fab; infectious disease; inflammation; single chain; single domain; therapeutic;
D O I
10.1517/14712598.3.7.1133
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Until recently, the concept of antibodies as in vivo therapeutics was still considered to be an exceedingly ambitious goal. However, in 2003, the situation has been completely transformed, with 14 FDA-approved monclonal antibodies (mAbs), 70 in late stage clinical (Phase II+) trials and > 1000 in preclinical development. The driving force behind this reversal in fortune has been advances in antibody engineering and the emergence of novel discovery techniques which overcame stability and immunogenicity issues that had blighted previous clinical trials of murine antibodies. For indications as diverse as inflammation, cancer and infectious disease, it is clear that unique properties of antibodies make them safe, effective and versatile therapeutics. These drugs can be used to neutralise pathogens, toxins and endogenous mediators of pathology. As cell targeting reagents, antibodies can be used to modulate cytoplasmic cascades or to 'tag' specific cells for complement- or effector-mediated lysis. Antibodies can also be modified to deliver toxic or modulatory payloads (small molecules, radionuclides and enzymes) and engineered to bind multiple epitopes (bispecifics) or even to have novel catalytic activity (abzymes). The modular structure of immunoglobulins and the availability of antibody fragment libraries also make it possible to produce variable-domain therapeutics (Fab, single-chain and domain antibodies). Although exhibiting less favourable kinetics in vivo, these fragments are simple to express and have an increased tissue penetration, making them especially useful as neutralising agents or in the delivery of payload. The number of approved antibodies is expected to increase arithmetically in the near term, as the platform is adopted as a valid alternative to small molecule discovery. This review provides an introduction to the antibody discovery process and discusses the past, present and future applications of therapeutic antibodies, with reference to several FDA-approved precedents.
引用
收藏
页码:1133 / 1152
页数:20
相关论文
共 195 条
[1]  
Adams GP, 2001, CANCER RES, V61, P4750
[2]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[3]   A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 [J].
Armbruster, C ;
Stiegler, GM ;
Vcelar, BA ;
Jäger, W ;
Michael, NL ;
Vetter, N ;
Katinger, HWD .
AIDS, 2002, 16 (02) :227-233
[4]  
Babb J D, 1995, J Atheroscler Thromb, V2, P1
[5]   INTERACTION OF IGE WITH ITS HIGH-AFFINITY RECEPTOR - STRUCTURAL BASIS AND REQUIREMENTS FOR EFFECTIVE CROSS-LINKING [J].
BAIRD, B ;
SHOPES, RJ ;
OI, VT ;
ERICKSON, J ;
KANE, P ;
HOLOWKA, D .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1989, 88 (1-2) :23-28
[6]  
BARRY MA, 1994, BIOTECHNIQUES, V16, P616
[7]  
Bayés M, 2002, METHOD FIND EXP CLIN, V24, P371
[8]   Yeast surface display for screening combinatorial polypeptide libraries [J].
Boder, ET ;
Wittrup, KD .
NATURE BIOTECHNOLOGY, 1997, 15 (06) :553-557
[9]   Role of natural and immune IgM antibodies in immune responses [J].
Boes, M .
MOLECULAR IMMUNOLOGY, 2000, 37 (18) :1141-1149
[10]   Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates [J].
Boon, L ;
Holland, B ;
Gordon, W ;
Liu, P ;
Shiau, F ;
Shanahan, W ;
Reimann, KA ;
Fung, M .
TOXICOLOGY, 2002, 172 (03) :191-203